Literature DB >> 1661131

Identification and cloning of a novel amplified DNA sequence in human malignant fibrous histiocytoma derived from a region of chromosome 12 frequently rearranged in soft tissue tumors.

P S Meltzer1, S A Jankowski, P Dal Cin, A A Sandberg, I B Paz, M A Coccia.   

Abstract

Amplification of cellular oncogenes occurs frequently in several human cancers and is an important mechanism of increased gene expression. Identification of amplified genes in tumor cells has proved to be a useful approach for understanding genetic alterations in cancer. Previous procedures for isolating probes from amplified DNA sequences have relied on tissue culture cells, limiting the range of tumors that can be studied and raising questions of in vitro artifact. We have circumvented these problems by combining in gel renaturation of amplified sequences with the polymerase chain reaction. Using this approach, we have identified and partially cloned a DNA amplification unit from biopsies of human malignant fibrous histiocytoma. This amplification unit is derived from chromosome 12q13-14, a site commonly involved in rearrangements in soft tissue tumors, and contains at least one transcribed region (designated SAS, for sarcoma amplified sequence).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1661131

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  13 in total

1.  Comparative genomic hybridization of malignant fibrous histiocytoma reveals a novel prognostic marker.

Authors:  M L Larramendy; M Tarkkanen; C Blomqvist; M Virolainen; T Wiklund; S Asko-Seljavaara; I Elomaa; S Knuutila
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

2.  Direct isolation of genes encoded within a homogeneously staining region by chromosome microdissection.

Authors:  Y A Su; J M Trent; X Y Guan; P S Meltzer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

3.  Local mesenchymal stem/progenitor cells are a preferential target for initiation of adult soft tissue sarcomas associated with p53 and Rb deficiency.

Authors:  Jinhyang Choi; Stephen J Curtis; David M Roy; Andrea Flesken-Nikitin; Alexander Yu Nikitin
Journal:  Am J Pathol       Date:  2010-09-23       Impact factor: 4.307

Review 4.  Osteosarcoma development and stem cell differentiation.

Authors:  Ni Tang; Wen-Xin Song; Jinyong Luo; Rex C Haydon; Tong-Chuan He
Journal:  Clin Orthop Relat Res       Date:  2008-06-18       Impact factor: 4.176

Review 5.  The Role of MDM2 Amplification and Overexpression in Tumorigenesis.

Authors:  Jonathan D Oliner; Anne Y Saiki; Sean Caenepeel
Journal:  Cold Spring Harb Perspect Med       Date:  2016-06-01       Impact factor: 6.915

6.  Is the EWS/FLI-1 fusion transcript specific for Ewing sarcoma and peripheral primitive neuroectodermal tumor? A report of four cases showing this transcript in a wider range of tumor types.

Authors:  P Thorner; J Squire; S Chilton-MacNeil; P Marrano; J Bayani; D Malkin; M Greenberg; A Lorenzana; M Zielenska
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

7.  Coamplification on chromosomes 7p12-13 and 9q12-13 identified by reverse chromosome painting in a glioblastoma multiforme.

Authors:  U Fischer; B Wullich; H P Sattler; E Göttert; K D Zang; E Meese
Journal:  Hum Genet       Date:  1994-03       Impact factor: 4.132

8.  Expression of growth factor receptors, the focal adhesion kinase, and other tyrosine kinases in human soft tissue tumors.

Authors:  T M Weiner; E T Liu; R J Craven; W G Cance
Journal:  Ann Surg Oncol       Date:  1994-01       Impact factor: 5.344

9.  A long range restriction map spanning the myxoid liposarcoma breakpoint in the q13-14 region of human chromosome 12.

Authors:  A Forus; P F Kools; E F Schoenmakers; W J Van de Ven; O Myklebost
Journal:  Hum Genet       Date:  1994-09       Impact factor: 4.132

10.  Liposarcoma: molecular genetics and therapeutics.

Authors:  Rachel Conyers; Sophie Young; David M Thomas
Journal:  Sarcoma       Date:  2010-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.